Literature DB >> 8894585

In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.

F Crokaert1, M Aoun, V Duchateau, P Grenier, A Vandermies, J Klastersky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8894585     DOI： 10.1007/bf01691164

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  7 in total

1.  Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).

Authors:  R Wise; D Mortiboy; J Child; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

2.  Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Authors:  M M París; S M Hickey; M Trujillo; S Shelton; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

Review 3.  New quinolones and gram-positive bacteria.

Authors:  L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

4.  In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.

Authors:  P M Roblin; G Montalban; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

5.  In vitro activity of the new fluoroquinolone CP-99,219.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 6.  Lower respiratory tract infection therapy--the role of ciprofloxacin.

Authors:  A P Ball; G S Tillotson
Journal:  J Int Med Res       Date:  1995 Sep-Oct       Impact factor: 1.671

7.  In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.

Authors:  A E Girard; D Girard; T D Gootz; J A Faiella; C R Cimochowski
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191
  7 in total
  5 in total

1.  An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin.

Authors:  L Purkins; S D Oliver; S A Willavize
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

2.  In vitro activity of trovafloxacin against Chlamydia pneumoniae.

Authors:  P M Roblin; A Kutlin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

Review 4.  Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.

Authors:  J C Pechère; T D Gootz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

5.  Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group.

Authors:  B O'Doherty; R Daniel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.